Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider an implantable bone-conduction (bone-anchored) hearing aid as an alternative to an air-conduction contralateral routing of signal hearing aid in patients five years of age and older with single-sided sensorineural deafness and normal hearing in the other ear. The pure tone average air conduction threshold of the normal ear should be better than 20 decibel (dB) measured at 0.5, 1, 2, and 3 kilohertz (kHz) to be eligible for coverage.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider the use of unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aid(s) as an alternative to air-conduction hearing aid in patients with a conductive or mixed hearing loss to be eligible for coverage.**

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date:  06/24/2002
Current Effective Date:  03/13/2023

Patient Selection Criteria
Coverage eligibility for the use of unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aids as an alternative to an air-conduction hearing aid in patients 5 years of age and older with a conductive or mixed hearing loss will be considered when at least 1 of the following criteria are met:

- Congenital or surgically induced malformations (e.g., atresia) of the external ear canal or middle ear; OR
- Chronic external otitis or otitis media; OR
- Tumors of the external canal and/or tympanic cavity; OR
- Dermatitis of the external canal; AND

Meet the following audiologic criteria
- For percutaneous devices, A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kilohertz (kHz) of better than or equal to 45 decibel (dB) (OBC and BP100 devices), 55 decibel (dB) (Intenso device) or 65 decibel (dB) (Cordele II device).
- For transcutaneous devices, A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kilohertz (kHz) of better than or equal to 45 decibel (dB) (BAHA Attract and Sophono (passive) devices) or 55 decibel (dB) (Cochlear Osia and Med-El Bonebridge (active) devices).
- For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone conduction threshold of less than 10 decibel (dB) on average measured at 0.5, 1, 2 and 3 kilohertz (kHz), (4 kHz for OBC and Ponto Pro) or less than 15 decibel (dB) at individual frequencies.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers other uses of implantable bone-conduction (bone-anchored) hearing aids, including use in patients with bilateral sensorineural hearing loss, to be investigational.*
Based on review of available data, the Company considers implantable bone conduction hearing aids when patient selection criteria are not met to be investigational.*

**Policy Guidelines**

In patients being considered for implantable bone-conduction (bone-anchored) hearing aid(s), skull bone quality and thickness should be assessed for adequacy to ensure implant stability. Additionally, patients (or caregivers) must be able to perform proper hygiene to prevent infection and ensure the stability of the implants and percutaneous abutments.

**Background/Overview**

**Hearing Loss**

Hearing loss is described as conductive, sensorineural, or mixed, and can be unilateral or bilateral. Normal hearing detects sound at or below 20 decibels (dB). The American Speech Language Hearing Association has defined degree of hearing loss based on pure-tone average detection thresholds as mild (20-40 dB), moderate (40-60 dB), severe (60-80 dB), and profound (≥80 dB). Pure-tone average is calculated by averaging hearing sensitivities (ie, the minimum volume that a patient hears) at multiple frequencies (perceived as pitch), typically within the range of 0.25 to 8 kHz.

Sound amplification using an air-conduction (AC) hearing aid can provide benefit to patients with sensorineural or mixed hearing loss. Contralateral routing of signal (CROS) is a system in which a microphone on the affected side transmits a signal to an AC hearing aid on the normal or less affected side.

**Treatment**

External bone-conduction hearing devices function by transmitting sound waves through the bone to the ossicles of the middle ear. The external devices must be applied close to the temporal bone, with either a steel spring over the top of the head or a spring-loaded arm on a pair of spectacles. These devices may be associated with pressure headaches or soreness.

A bone-anchored implant system combines a vibrational transducer coupled directly to the skull via a percutaneous abutment that permanently protrudes through the skin from a small titanium implant anchored in the temporal bone. The system is based on osseointegration through which living tissue integrates with titanium in the implant over 3 to 6 months, conducting amplified and processed sound...
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

via the skull bone directly to the cochlea. The lack of intervening skin permits the transmission of vibrations at a lower energy level than required for external bone-conduction hearing aids. Implantable bone-conduction hearing systems are primarily indicated for people with conductive or mixed sensorineural or conductive hearing loss. They may also be used with CROS as an alternative to an AC hearing aid for individuals with unilateral sensorineural hearing loss.

Partially implantable magnetic bone-conduction hearing systems also referred to as transcutaneous bone-anchored systems, are an alternative to bone-conduction hearing systems that connect to bone percutaneously via an abutment. With this technique, acoustic transmission occurs transcutaneously via magnetic coupling of the external sound processor and the internally implanted device components. The bone-conduction hearing processor contains magnets that adhere externally to magnets implanted in shallow bone beds with the bone-conduction hearing implant. Because the processor adheres magnetically to the implant, there is no need for a percutaneous abutment to physically connect the external and internal components. To facilitate greater transmission of acoustics between magnets, skin thickness may be reduced to 4 to 5 mm over the implant when it is surgically placed.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Several implantable bone-conduction hearing systems have been approved by the U.S. FDA for marketing through the 510(k) process (Table 1).

Product codes: MAH, LXB

Table 1. Implantable Bone-Conduction Hearing Systems Approved by the FDA

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baha® Auditory Osseointegrated Implant System</td>
<td>Cochlear Americas</td>
<td></td>
<td>K182116</td>
</tr>
<tr>
<td>BA310 Abutment, BIA310 Implant/Abutment</td>
<td></td>
<td>Dec 2018</td>
<td></td>
</tr>
</tbody>
</table>
**Implantable Bone-Conduction and Bone-Anchored Hearing Aids**

**Policy #** 00004  
**Original Effective Date:** 06/24/2002  
**Current Effective Date:** 03/13/2023

<table>
<thead>
<tr>
<th>Device Description</th>
<th>Approval Date</th>
<th>Manufacturer Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baha 5 Power Sound Processor</td>
<td>May 2016</td>
<td>K161123</td>
</tr>
<tr>
<td>Baha 5 Super Power Sound Processor</td>
<td>Mar 2016</td>
<td>K153245</td>
</tr>
<tr>
<td>Baha®⩆ 5 Sound Processor</td>
<td>Mar 2015</td>
<td>K142907</td>
</tr>
<tr>
<td>Baha®⩆ Attract System</td>
<td>Nov 2013</td>
<td>K131240</td>
</tr>
<tr>
<td>Baha®⩆ Cordelle II</td>
<td>Jul 2015</td>
<td>K150751</td>
</tr>
<tr>
<td>Baha Divino®⩆</td>
<td>Aug 2004</td>
<td>K042017</td>
</tr>
<tr>
<td>Baha Intenso®⩆ (digital signal processing)</td>
<td>Aug 2008</td>
<td>K081606</td>
</tr>
<tr>
<td>Baha®⩆ 4 (upgraded from the BP100)</td>
<td>Sep 2013</td>
<td>K132278</td>
</tr>
<tr>
<td>Cochlear™⩆ Osia™2 ⩆ System</td>
<td>Dec 2019</td>
<td>K191921</td>
</tr>
<tr>
<td>OBC Bone-Anchored Hearing Aid System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ponto Bone-Anchored Hearing System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ponto 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ponto 3, Ponto 3 Power and Ponto 3 SuperPower</td>
<td>Sep 2016</td>
<td>K161671</td>
</tr>
</tbody>
</table>

The FDA cleared the majority of these systems for use in children ages 5 years and older and adults for the following indications:

- Patients who have conductive or mixed hearing loss and can still benefit from sound amplification;
- Patients with bilaterally symmetric conductive or mixed hearing loss, may be implanted bilaterally;
- Patients with sensorineural deafness in 1 ear and normal hearing in the other (ie, single-sided deafness);
- Patients who are candidates for an AC CROS hearing aid but who cannot or will not wear an AC CROS device.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004  
Original Effective Date:  06/24/2002  
Current Effective Date:  03/13/2023

Baha sound processors can be used with the Baha Softband™. With this application, there is no implantation surgery. The sound processor is attached to the head using a hard or soft headband. The amplified sound is transmitted transcutaneously to the cochlea via the bones of the skull. In 2002, the Baha Softband was cleared for marketing by FDA for use in children younger than 5 years. Because this application has no implanted components, it is not addressed in this evidence review.

The most recently cleared Osia™ system may be used by adults and children 12 years of age and older with conductive hearing loss, mixed hearing loss, and single-sided sensorineural deafness.

The FDA also cleared 3 partially implantable magnetic bone-conduction devices for marketing through the 510(k) process (Table 2).

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonebridge</td>
<td>MED-EL</td>
<td>Mar 2019</td>
<td>K183373</td>
</tr>
<tr>
<td>Otomag™ Bone-Conduction Hearing System</td>
<td>Medtronic (Formerly Sophono)</td>
<td>Nov 2013</td>
<td>K132189</td>
</tr>
<tr>
<td>Cochlear Baha® 4 Sound Processor</td>
<td>Cochlear Americas</td>
<td>Oct 2012</td>
<td>K121317</td>
</tr>
</tbody>
</table>

The SoundBite™ Hearing System (Sonitus Medical, San Mateo, CA) is an intraoral bone-conducting hearing prosthesis that consists of a behind-the-ear microphone and an in-the-mouth hearing device. In 2011, it was cleared for marketing by FDA through the 510(k) process for indications similar to the Baha. However, the manufacturer, Sonitus Medical, closed in 2015.

FDA product code (for bone-anchoring hearing aid): LXB. FDA product code (for implanted bone-conduction hearing aid): MAH.

**Rationale/Source**
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date:  06/24/2002
Current Effective Date:  03/13/2023

practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Sensorineural, conductive, and mixed hearing loss may be treated with various devices, including conventional air-conduction or bone-conduction external hearing aids. Air-conduction hearing aids may not be suitable for patients with chronic middle ear and ear canal infections, atresia of the external canal, or an ear canal that cannot accommodate an ear mold. Bone-conduction hearing aids may be useful for individuals with conductive hearing loss, or (if used with contralateral routing of signal), for unilateral sensorineural hearing loss. Implantable, bone-anchored hearing aids (BAHAs) that use a percutaneous or transcutaneous connection to a sound processor have been investigated as alternatives to conventional bone-conduction hearing aids for patients with conductive or mixed hearing loss or for patients with unilateral single-sided sensorineural hearing loss.

Review of Evidence - Intro
For individuals who have conductive or mixed hearing loss who receive an implantable BAHA with a percutaneous abutment or a partially implantable BAHA with transcutaneous coupling to the sound processor, the evidence includes observational studies that have reported pre-post differences in hearing parameters after treatment with BAHAs. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. No prospective trials were identified. Observational studies reporting on within-subjects changes in hearing have generally reported hearing improvements with the devices. Given the objectively measured outcomes and the largely invariable natural history of hearing loss in individuals who would be eligible for an implantable bone-conduction device, the demonstrated improvements in hearing after device placement can be attributed to the device. Studies of partially implantable BAHAs have similarly demonstrated within-subjects improvements in hearing. The single-arm studies have shown improvements in hearing in the device-aided state. No direct comparisons other than within-individual comparisons with external hearing aids were identified, but, for individuals unable to wear an external hearing aid, there may be few alternative treatments. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unilateral sensorineural hearing loss who receive a fully or partially implantable BAHA with the contralateral routing of signal, the evidence includes an RCT, multiple prospective and retrospective case series, and a systematic review. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Single-arm case series, with sample sizes
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

ranging from 9 to 180 patients, have generally reported improvements in patient-reported speech quality, speech perception in noise, and satisfaction with bone-conduction devices with contralateral routing of the signal. However, a well-conducted systematic review of studies comparing bone-anchored devices with hearing aids using contralateral routing of signal found no evidence of improvement in speech recognition or hearing localization. The single RCT included in the systematic review was a pilot study enrolling only 10 patients and, therefore, does not provide definitive evidence. Quality RCTs on BAHA for unilateral sensorineural hearing loss are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information
For patients with single-sided sensorineural deafness, a binaural hearing benefit may be provided by way of contralateral routing of signals to the hearing ear. There is evidence that bilateral hearing assistance devices improve hearing to a greater degree than unilateral devices. BAHAs may be considered an alternative to external devices in patients who are not candidates for external devices. By extension, the use of an implantable bone-conduction device with contralateral routing of the signal may be considered medically necessary in patients with unilateral sensorineural deafness.

2016 Clinical Input
Input focused on the categorization of partially implantable bone-anchored devices relative to fully implantable devices. There was a strong consensus that partially implantable devices are considered an evolution of earlier devices, and that direct trials comparing the 2 are not necessary.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2016 Clinical Input
In response to requests, input was received from 2 specialty societies and 3 academic medical centers (1 of which provided 4 responses and 1 of which provided 3 responses) while this policy was under
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

Review in 2016. Input focused on the categorization of partially implantable bone-anchored devices relative to fully implantable devices. There was a strong consensus that partially implantable devices are considered an evolution of earlier devices, and that direct trials comparing the 2 are not necessary.

**Practice Guidelines and Position Statements**
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

In 2021, the American Academy of Otolaryngology Head and Neck Surgery updated its position statement on the use of implantable hearing devices. It states that the Academy considers bone conduction hearing devices (BCHD) as appropriate, and in some cases preferred, for the treatment of conductive and mixed hearing loss. BCHD may also be indicated in select patients with single-sided deafness. BCHD include semi-implantable bone conduction devices utilizing either a percutaneous or transcutaneous attachment, as well as bone conduction oral appliances and scalp-worn devices. The recommendation for BCHD should be determined by a qualified otolaryngology-head and neck surgeon. These devices are approved by the Food and Drug Administration (FDA) for these indications, and their use should adhere to the restrictions and guidelines specified by the appropriate governing agency, such as the FDA in the United States and the respective regulatory agencies in countries other than the United States."

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
There is no national coverage determination. The Medicare Benefit Policy Manual references hearing aids and auditory implants, stating that hearing aids are excluded from coverage, including air-conduction and bone-conduction devices. However, devices producing the perception of sound by replacing the function of the middle ear, cochlea, or auditory nerve are payable by Medicare as prosthetic devices. These devices are indicated only when hearing aids are medically inappropriate or cannot be used. Along with cochlear and auditory brainstem implants, the benefits manual specifically refers to osseointegrated implants as prosthetic devices. In 2014, Medicare clarified its
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

hearing aid coverage to state that “certain auditory implants, including cochlear implants, brain stem implants, and osseointegrated implants, do not meet the definition of hearing aids that are excluded from coverage.”

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03533686</td>
<td>Comparative Study of Non-invasive Adhear Bone Conduction System to Traditional Bone Conduction Hearing Devices</td>
<td>90</td>
<td>Sep 2022 (Status = Recruiting)</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01858246</td>
<td>A Randomized Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge</td>
<td>60</td>
<td>Dec 2017 (Completed, last updated 2018)</td>
</tr>
<tr>
<td>NCT02022085a</td>
<td>Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)</td>
<td>2</td>
<td>Nov 2017 (Completed, last updated 2018)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

References
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023


Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date:  06/24/2002
Current Effective Date:  03/13/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004  
Original Effective Date: 06/24/2002  
Current Effective Date: 03/13/2023


Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date:  06/24/2002
Current Effective Date:  03/13/2023

Policy History
Original Effective Date:  06/24/2002
Current Effective Date:  03/13/2023
06/11/2002  Medical Director review
06/20/2002  Medical Policy Committee review
06/24/2002  Managed Care Advisory Council approval. Format revision. No substance change to policy.
07/06/2004  Medical Director review
07/20/2004  Medical Policy Committee review. Format revision, Rationale/Source added to policy. No substance change to policy.
07/26/2004  Managed Care Advisory Council approval
06/07/2005  Medical Director review
06/21/2005  Medical Policy Committee review. Clinical criteria change. Coverage for single sided deafness and bilateral fittings added as investigational indication.
07/15/2005  Managed Care Advisory Council approval
06/13/2006  Format revisions. No changes to policy statement.
08/02/2006  Medical Director review
08/09/2006  Medical Policy Committee approval. Patient selection criteria updated to include age limitations.
10/10/2007  Medical Director review
10/17/2007  Medical Policy Committee approval. Policy statements updated and clarified related to eligibility for coverage for unilateral and bilateral sensorineural hearing loss. Policy statement added concerning investigational uses, including bilateral sensorineural hearing loss. Policy title changed to add “and Bone-Anchored”.
10/01/2008  Medical Director review
10/22/2008  Medical Policy Committee approval. No change to coverage eligibility.
10/01/2009  Medical Policy Committee approval
10/14/2009  Medical Policy Implementation Committee approval. No change to coverage eligibility.
10/14/2010  Medical Policy Committee review
10/20/2010  Medical Policy Implementation Committee approval. The age requirement in the coverage language changed to be consistent with FDA-approved labeling from “patients over five years of age” to “patients five years of age and older”. Coverage
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy #  00004  
Original Effective Date:  06/24/2002  
Current Effective Date:  03/13/2023

...that stands alone without criteria placed under the subtitle “When Services Are Eligible for Coverage”.

02/01/2011  Coding updated
10/06/2011  Medical Policy Committee review
10/19/2011  Medical Policy Implementation Committee approval. Audiologic criteria revised to read: A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kHz of better than or equal to 45 dB (OBC and BP100 devices), 55 dB (Intenso device) or 65 dB (Cordele II device). For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone conduction threshold of less than 10 dB on average measured at 0.5, 1, 2 and 3 kHz, or less than 15 dB at individual frequencies.

10/11/2012  Medical Policy Committee review
10/31/2012  Medical Policy Implementation Committee approval. Added investigational statement for partially implantable hearing systems.

02/04/2013  Coding updated
10/03/2013  Medical Policy Committee review
10/16/2013  Medical Policy Implementation Committee approval. No change to coverage.
10/02/2014  Medical Policy Committee review
10/15/2014  Medical Policy Implementation Committee approval. No change to coverage.
10/08/2015  Medical Policy Committee review
10/21/2015  Medical Policy Implementation Committee approval. No change to coverage.
10/06/2016  Medical Policy Committee review
10/19/2016  Medical Policy Implementation Committee approval. Policy statements changed to remove investigational statement for partially implantable devices.

01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes
10/05/2017  Medical Policy Committee review
10/18/2017  Medical Policy Implementation Committee approval. No change to coverage.
01/01/2018  Coding update
10/04/2018  Medical Policy Committee review
10/17/2018  Medical Policy Implementation Committee approval. No change to coverage.
10/03/2019  Medical Policy Committee review
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 03/13/2023

10/01/2020 Medical Policy Committee review
02/04/2021 Medical Policy Committee review
02/10/2021 Medical Policy Implementation Committee approval. New FDA approved devices added to policy. Criteria revised to “For transcutaneous devices, A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kilohertz (kHz) of better than or equal to 45 decibel (dB) (BAHA Attract and Sophono (passive) devices) or 55 decibel (dB) (Cochlear Osia and Med-El Bonebridge (active) devices).
02/03/2022 Medical Policy Committee review
02/09/2022 Medical Policy Implementation Committee approval. No change to coverage.
12/07/2022 Coding update
02/02/2023 Medical Policy Committee review
02/08/2023 Medical Policy Implementation Committee approval. No change to coverage.
Next Scheduled Review Date: 02/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy
Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Policy # 00004  
Original Effective Date: 06/24/2002  
Current Effective Date: 03/13/2023

Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>69710, 69711, 69714, 69717, 69716, 69719, 69726, 69727, 69799</td>
</tr>
<tr>
<td></td>
<td>Delete codes effective 1/1/2022: 69715, 69718</td>
</tr>
<tr>
<td></td>
<td>Add codes effective 1/1/2023: 69728, 69729, 69730</td>
</tr>
<tr>
<td>HCPCS</td>
<td>L8625, L8690, L8691, L8693, L8694</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.